IRTC / iRhythm Holdings, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2026 iRhythm Holdings, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2026 iRhythm Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 41-3421287 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2026 iRhythm Holdings, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2026 iRhythm Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 41-3421287 (State or other jurisdiction of incorporation or organization)

As filed with the Securities and Exchange Commission on May 27, 2026

As filed with the Securities and Exchange Commission on May 27, 2026 Registration No.

Calculation of Filing Fee Table Form S-8 (Form Type) iRhythm Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Propose

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) iRhythm Holdings, Inc.

EXHIBIT 99.1 IRHYTHM HOLDINGS, INC. 2026 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of th

exhibit9912026equityinc EXHIBIT 99.1 IRHYTHM HOLDINGS, INC. 2026 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Holdings, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37918 41-3421287 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 699 8th Street, Suite 600 San Francisco, California 94103 (Address of pri

iRhythm Holdings, Inc. Conflict Minerals Report For the Reporting Period from January 1, 2025 to December 31, 2025

Exhibit 1.01 iRhythm Holdings, Inc. Conflict Minerals Report For the Reporting Period from January 1, 2025 to December 31, 2025 This Conflict Minerals Report ("Report"), of iRhythm Holdings, Inc. ("the Company", “we,” “us” or “our”), for the period from January 1, 2025 to December 31, 2025 ("the Reporting Period"), has been prepared pursuant to Rule 13p-1 ("Rule 13p-1" or "the Rule") under the Sec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Holdings, Inc. (Exact Name of Regis

IRHYTHM HOLDINGS, INC. 2026 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, an

irtc-2026equityincentive IRHYTHM HOLDINGS, INC. 2026 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2026 iRhythm Holdings,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2026 iRhythm Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 41-3421287 (State or other jurisdiction of incorporation or organizatio

iRhythm Holdings Announces First Quarter 2026 Financial Results

Exhibit 99.1 iRhythm Holdings Announces First Quarter 2026 Financial Results SAN FRANCISCO, April 30, 2026 - iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Highlights •Revenue of $199.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2026 iRhythm Holdings,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2026 iRhythm Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 41-3421287 (State or other jurisdiction of incorporation or organizatio

March 31, 2026 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by iRhythm Holdings, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Co

electronicpwcex16lettert March 31, 2026 Securities and Exchange Commission 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2026 iRhythm Holdings,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2026 iRhythm Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 41-3421287 (State or other jurisdiction of incorporation or organizatio

iRhythm Holdings Appoints Jason Patten to its Board of Directors SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict

jpattenprv2 iRhythm Holdings Appoints Jason Patten to its Board of Directors SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) - iRhythm Holdings, Inc.

39530/00003/FW/25578804.2 IRHYTHM HOLDINGS, INC. 2006 STOCK PLAN (Amended as of October 28, 2010) 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, t

ex1062006stockplanagreem 39530/00003/FW/25578804.2 IRHYTHM HOLDINGS, INC. 2006 STOCK PLAN (Amended as of October 28, 2010) 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2026 iRhythm Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2026 iRhythm Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 41-3421287 (State or other jurisdiction of incorporation or organiza

1 IRHYTHM HOLDINGS, INC. AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY Adopted October 29, 2025; Assumed January 12, 2026 This Amended and Restated Executive Change in Control and Severance Policy, as amended (the “Policy”) is

ex109irtcpost-reorgarex 1 IRHYTHM HOLDINGS, INC. AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY Adopted October 29, 2025; Assumed January 12, 2026 This Amended and Restated Executive Change in Control and Severance Policy, as amended (the “Policy”) is designed to provide certain protections to a select group of key employees of iRhythm Holdings, Inc. (the “Company”) or any o

IRHYTHM HOLDINGS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is effective as of the last signature hereto (the “Agreement Effective Date”) and is between iRhythm Holdings, Inc., a Delaware corporation (the “Compa

ex108irhythmholdings-for IRHYTHM HOLDINGS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is effective as of the last signature hereto (the “Agreement Effective Date”) and is between iRhythm Holdings, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals

iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results

Exhibit 99.1 iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results SAN FRANCISCO, February 19, 2026 (GLOBE NEWSWIRE) - iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2025. Fourt

IRHYTHM HOLDINGS, INC. COMPENSATION RECOVERY POLICY (Effective August 10, 2023 when adopted by iRhythm Technologies, Inc.; assumed by iRhythm Holdings, Inc. on January 12, 2026) The Board has determined that it is in the best interests of the Company

ex971irtc-holdcocompensa IRHYTHM HOLDINGS, INC. COMPENSATION RECOVERY POLICY (Effective August 10, 2023 when adopted by iRhythm Technologies, Inc.; assumed by iRhythm Holdings, Inc. on January 12, 2026) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company and/or its subsidiaries to recover from specified current and

IRHYTHM HOLDINGS, INC. 2016 EQUITY INCENTIVE PLAN As amended November 7, 2024. 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide addi

ex1042016eipamended2024a IRHYTHM HOLDINGS, INC. 2016 EQUITY INCENTIVE PLAN As amended November 7, 2024. 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan pe

Exhibit 22.1 List of Issuers of Guaranteed Securities As of December 31, 2025, the following wholly-owned subsidiary of iRhythm Holdings, Inc. was the issuer of the 1.50% Convertible Senior Notes due 2029, which are guaranteed by iRhythm Holdings, In

irtc-ex221 Exhibit 22.1 List of Issuers of Guaranteed Securities As of December 31, 2025, the following wholly-owned subsidiary of iRhythm Holdings, Inc. was the issuer of the 1.50% Convertible Senior Notes due 2029, which are guaranteed by iRhythm Holdings, Inc. Name of Subsidiary Jurisdiction of Incorporation iRhythm Technologies, Inc. Delaware

Exhibit 21.1 List of Subsidiaries Company Name Place of Incorporation iRhythm Technologies, Inc. Delaware iRhythm Technologies Ltd. United Kingdom iRhythm Technologies Netherlands B.V. The Netherlands iRhythm Singapore PTE. Ltd. Singapore iRhythm Jap

ex211listofsubsidiaries Exhibit 21.1 List of Subsidiaries Company Name Place of Incorporation iRhythm Technologies, Inc. Delaware iRhythm Technologies Ltd. United Kingdom iRhythm Technologies Netherlands B.V. The Netherlands iRhythm Singapore PTE. Ltd. Singapore iRhythm Japan GK (1) Japan iRhythm Philippines, Inc. (1) Philippines (1) iRhythm Japan GK and iRhythm Philippines, Inc. are indirect subs

1 INSIDER TRADING POLICY This policy was approved by the Board of Directors of iRhythm Technologies, Inc. on February 5, 2025 and assumed by iRhythm Holdings, Inc. on January 12, 2026 PURPOSE iRhythm Holdings, Inc. (together with its subsidiaries, th

ex191irhythmholdings-ins 1 INSIDER TRADING POLICY This policy was approved by the Board of Directors of iRhythm Technologies, Inc.

39530/00003/FW/25575301.2 IRHYTHM HOLDINGS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN (as amended February 27, 2019) 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase

ex1052016esppamended2019 39530/00003/FW/25575301.2 IRHYTHM HOLDINGS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN (as amended February 27, 2019) 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a Code Section 423 C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-3791

As filed with the U.S. Securities and Exchange Commission on January 12, 2026

As filed with the U.S. Securities and Exchange Commission on January 12, 2026 Registration No. 333-263066 Registration No. 333-256762 Registration No. 333-236838 Registration No. 333-233033 Registration No. 333-223351 Registration No. 333-217077 Registration No. 333-214203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-26

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is entered into as of January 12, 2026, by and among iRhythm Technologies, Inc., a Delaware corporation (the “Company”), LTCM Holdings, Inc. (“Holdco”) and a direct, wholly owned subsidiary of the Company, and LTCM Merger Sub, Inc., a Delaware corporation (“Merger Sub

AMENDED AND RESTATED BYLAWS OF IRHYTHM HOLDINGS, INC. (As Amended and Restated on January 12, 2026) TABLE OF CONTENTS

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF IRHYTHM HOLDINGS, INC. (As Amended and Restated on January 12, 2026) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1        REGISTERED OFFICE 1 1.2        OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1        PLACE OF MEETINGS 1 2.2        ANNUAL MEETING 1 2.3        SPECIAL MEETING 1 2.4        ADVANCE NOTICE PROCEDURES 2 2.5     

As filed with the U.S. Securities and Exchange Commission on January 12, 2026

As filed with the U.S. Securities and Exchange Commission on January 12, 2026 Registration No. 333-263066 Registration No. 333-256762 Registration No. 333-236838 Registration No. 333-233033 Registration No. 333-223351 Registration No. 333-217077 Registration No. 333-214203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-26

____________________________________________ IRHYTHM TECHNOLOGIES, INC., AS COMPANY, IRHYTHM HOLDINGS, INC., AS GUARANTOR, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE First Supplemental Indenture Dated as of January 12, 2026 to the Date

Exhibit 4.2 IRHYTHM TECHNOLOGIES, INC., AS COMPANY, IRHYTHM HOLDINGS, INC., AS GUARANTOR, and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE First Supplemental Indenture Dated as of January 12, 2026 to the Indenture Dated as of March 7, 2024 FIRST SUPPLEMENTAL INDENTURE This FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of January 12, 2026, is by and betwe

© 2026 iRhythm Technologies, Inc. 1 iRhythm at the J.P. Morgan 44th Annual Healthcare Conference Quentin Blackford, President & Chief Executive Officer January 12, 2026 2 © 2026 iRhythm Technologies, Inc. 2 Cautionary statement re forward-looking sta

Exhibit 99.2 © 2026 iRhythm Technologies, Inc. 1 iRhythm at the J.P. Morgan 44th Annual Healthcare Conference Quentin Blackford, President & Chief Executive Officer January 12, 2026 2 © 2026 iRhythm Technologies, Inc. 2 Cautionary statement re forward-looking statements, non-GAAP measures and other matters Certain data in this presentation was obtained from various external sources, and neither “i

As filed with the U.S. Securities and Exchange Commission on January 12, 2026

As filed with the U.S. Securities and Exchange Commission on January 12, 2026 Registration No. 333-263066 Registration No. 333-256762 Registration No. 333-236838 Registration No. 333-233033 Registration No. 333-223351 Registration No. 333-217077 Registration No. 333-214203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-26

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 iRhythm Holdings, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.0001 per share. As used in this summary, the terms “iRhythm,” “the Company,” “we,” “our” and “

ASSIGNMENT AND ASSUMPTION AGREEMENT

Exhibit 10.1 ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) dated as of January 12, 2026, by and between iRhythm Technologies, Inc., a Delaware corporation (“Company”) and iRhythm Holdings, Inc. (f/k/a LTCM Holdings, Inc.), a Delaware corporation (“Holdco”) and a direct, wholly owned subsidiary of the Company. RECITALS WHEREAS, pursuant to that cert

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2026 iRhythm Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2026 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

CERTIFICATE OF MERGER FOR THE MERGER OF LTCM MERGER SUB, INC. WITH AND INTO IRHYTHM TECHNOLOGIES, INC. January 12, 2026 Pursuant to Section 251 of the General Corporation Law of the State of Delaware

Exhibit 3.3 CERTIFICATE OF MERGER FOR THE MERGER OF LTCM MERGER SUB, INC. WITH AND INTO IRHYTHM TECHNOLOGIES, INC. January 12, 2026 Pursuant to Section 251 of the General Corporation Law of the State of Delaware iRhythm Technologies, Inc., a Delaware corporation (the “Company”), does hereby certify to the following facts relating to the merger (the “Merger”) of LTCM Merger Sub, Inc., a Delaware co

As filed with the U.S. Securities and Exchange Commission on January 12, 2026

As filed with the U.S. Securities and Exchange Commission on January 12, 2026 Registration No. 333-263066 Registration No. 333-256762 Registration No. 333-236838 Registration No. 333-233033 Registration No. 333-223351 Registration No. 333-217077 Registration No. 333-214203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-26

As filed with the U.S. Securities and Exchange Commission on January 12, 2026

As filed with the U.S. Securities and Exchange Commission on January 12, 2026 Registration No. 333-263066 Registration No. 333-256762 Registration No. 333-236838 Registration No. 333-233033 Registration No. 333-223351 Registration No. 333-217077 Registration No. 333-214203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-26

As filed with the U.S. Securities and Exchange Commission on January 12, 2026

As filed with the U.S. Securities and Exchange Commission on January 12, 2026 Registration No. 333-263066 Registration No. 333-256762 Registration No. 333-236838 Registration No. 333-233033 Registration No. 333-223351 Registration No. 333-217077 Registration No. 333-214203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-26

LTCM HOLDINGS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

Exhibit 3.1 LTCM HOLDINGS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LTCM Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: A.            The name of the Corporation is LTCM Holdings, Inc., and the original Certificate of Incorporation of this Corporation was filed with the Secretary of State

As filed with the U.S. Securities and Exchange Commission on January 12, 2026

As filed with the U.S. Securities and Exchange Commission on January 12, 2026 Registration No. 333-263066 Registration No. 333-256762 Registration No. 333-236838 Registration No. 333-233033 Registration No. 333-223351 Registration No. 333-217077 Registration No. 333-214203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-26

iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference

Exhibit 99.1 iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, JANUARY 12, 2026 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2025 iRhythm Technol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or orga

iRhythm Technologies Proxy Off-Season Shareholder Outreach Fall 2025 © 2025 iRhythm Technologies, Inc. 2 Cautionary statement re forward-looking statements, non-GAAP measures and other matters Certain data in this presentation was obtained from vario

irtc2025off-seasonproxyo iRhythm Technologies Proxy Off-Season Shareholder Outreach Fall 2025 © 2025 iRhythm Technologies, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name

iRhythm Technologies Announces Third Quarter 2025 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Third Quarter 2025 Financial Results SAN FRANCISCO, October 30, 2025 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights •Re

1 IRHYTHM TECHNOLOGIES, INC. AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY Effective October 29, 2025 This Amended and Restated Executive Change in Control and Severance Policy, as amended (the “Policy”) is designed to provide

irtcchangeincontrolands 1 IRHYTHM TECHNOLOGIES, INC. AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY Effective October 29, 2025 This Amended and Restated Executive Change in Control and Severance Policy, as amended (the “Policy”) is designed to provide certain protections to a select group of key employees of iRhythm Technologies, Inc. (“iRhythm” or the “Company”) or any of i

IRHYTHM TECHNOLOGIES, INC. 2016 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT NOTICE OF GRANT OF RESTRICTED STOCK UNITS Unless otherwise defined herein, the terms defined in the 2016 Equity Incentive Plan (the “Plan”) shall have the sam

irtc2025formrsuagreemen IRHYTHM TECHNOLOGIES, INC. 2016 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT NOTICE OF GRANT OF RESTRICTED STOCK UNITS Unless otherwise defined herein, the terms defined in the 2016 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Grant of Restricted Stock Units (the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2025 iRhythm Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

144

144 0001860745 XXXXXXXX LIVE 0001388658 IRHYTHM TECHNOLOGIES, INC. 001-37918 699 8th Street Suite 600 San Francisco CA 94103 (415) 632-5700 DANIEL WILSON Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 5000 875000.00 32127763 09/03/2025 NASDAQ Common 12/31/2023 Restricted Stock ISSUER N 1159 12/31/2023 Not Applicable Common 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2025 iRhythm Technologie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

iRhythm Technologies Announces Second Quarter 2025 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Second Quarter 2025 Financial Results SAN FRANCISCO, July 31, 2025 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights •Revenue

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 3, 2025 iRhythm Technologies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 3, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

iRhythm Technologies Announces Board Member Retirements and New Director Appointments SAN FRANCISCO, JULY 7, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutio

iRhythm Technologies Announces Board Member Retirements and New Director Appointments SAN FRANCISCO, JULY 7, 2025 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2025 iRhythm Technologies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

iRhythm Technologies, Inc. Conflict Minerals Report for the reporting period January 1, 2024 to December 31, 2024

Exhibit 1.01 iRhythm Technologies Inc. Conflict Minerals Report For the Reporting Period from January 1, 2024 to December 31, 2024 This Conflict Minerals Report, ("Report"), of iRhythm Technologies Inc., ("the Company", “we” or “our”), for the period January 1, 2024 to December 31, 2024, ("the Reporting Period"), has been prepared pursuant to Rule 13p-1, ("Rule 13p-1" or "the Rule"), under the Sec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 699 8th Street, Suite 600 San Francisco, California 94103 (Address of

iRhythm Technologies Announces First Quarter 2025 Financial Results

Exhibit 99.1 iRhythm Technologies Announces First Quarter 2025 Financial Results SAN FRANCISCO, May 1, 2025 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights •Revenue of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of R

ARS

2024 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

, by and between the Registra

iRhythm Technologies, Inc. • 650 Townsend Street, Suite 500 • San Francisco, CA 94103 phone: 415.632.5700 • fax: 415.632.5701 • irhythmtech.com June 28, 2019 Daniel Wilson [email protected] Dear Dan: We are pleased to offer you the position of Executive Vice President, Strategy & Corporate Development with iRhythm Technologies, Inc. (the “Company”). If you decide to join us, you will recei

iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results SAN FRANCISCO, February 20, 2025 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 202

ulting Agreement dated August 28, 2024

Page 1 of 7 IRHYTHM TECHNOLOGIES, INC. SEPARATION AGREEMENT AND CONSULTING AGREEMENT This Separation Agreement and General Release of Claims (this “Agreement”) confirms the agreement between iRhythm Technologies, Inc. (the “Company”) and Brice Bobzien (“Executive”) concerning the terms of Executive’s separation, and offers certain payments and benefits in exchange for Executive’s agreement to a ge

List of Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries iRhythm Technologies Limited Company Name Place of Incorporation iRhythm Technologies Limited United Kingdom iRhythm Singapore PTE. Ltd. Singapore iRhythm Japan GK (1) Japan iRhythm Philippines, Inc. (1) Philippines iRhythm Technologies Netherlands B.V. Netherlands (1) This an indirect subsidiary through iRhythm Singapore PTE. Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Technol

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or orga

Insider Trading Policy

1 INSIDER TRADING POLICY THIS POLICY WAS APPROVED BY THE BOARD ON FEBRUARY 5, 2025 PURPOSE iRhythm Technologies, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2025 iRhythm Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, January 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading dig

iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

016 Equity Incentive Plan and related form agreements

IRHYTHM TECHNOLOGIES, INC. 2016 EQUITY INCENTIVE PLAN As amended November 7, 2024. 1.Purposes of the Plan. The purposes of this Plan are: •to attract and retain the best available personnel for positions of substantial responsibility, •to provide additional incentive to Employees, Directors and Consultants, and •to promote the success of the Company’s business. The Plan permits the grant of Incent

IRTC / iRhythm Technologies, Inc. / Artisan Partners Limited Partnership - SC 13G/A Passive Investment

SC 13G/A 1 d886768dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 1 )* iRhythm Technologies Inc. (Name of Issuer) Common Stock (Tit

IRTC / iRhythm Technologies, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* iRhythm Technologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 450056106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

JOINT FILING AGREEMENT

EX-99.1 2 d886768dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 11/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTI

IRTC / iRhythm Technologies, Inc. / SANDS CAPITAL MANAGEMENT, LLC - SC 13G/A Passive Investment

SC 13G/A 1 d871375dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO Section 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 4) * iRhythm Technologies, Inc. (Name of Issuer) Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name

echnology License Agreement dated August 30, 2024 between Registrant and BioIntelliSense, Inc.

***CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL*** TECHNOLOGY LICENSE AGREEMENT This Technology License Agreement (this “Agreement”) is entered into as of August 30, 2024 (the “Effective Date”) by and between iRhythm Technologies, Inc.

iRhythm Technologies Announces Third Quarter 2024 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Third Quarter 2024 Financial Results SAN FRANCISCO, October 30, 2024 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024. Third Quarter 2024 Financial Highlights •Re

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

iRhythm Technologies Shareholder Engagement Fall 2024 2© 2024 iRhythm Technologies, Inc. BUSINESS OVERVIEW & YTD 2024 ACCOMPLISHMENTS CORPORATE GOVERNANCE & BOARD COMPOSITION Agenda for upcoming dialogue EXECUTIVE COMPENSATION SUSTAINABILITY & CORPOR

iRhythm Technologies Shareholder Engagement Fall 2024 2© 2024 iRhythm Technologies, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2024 iRhythm Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organi

Exhibit 99.1 iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerom

Exhibit 99.1 iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring (ACM) market SAN FRANCISCO, SEPTEMBER 4, 2024

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

iRhythm Technologies Announces Second Quarter 2024 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Second Quarter 2024 Financial Results SAN FRANCISCO, August 1, 2024 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024. Second Quarter 2024 Financial Highlights •Revenue

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of Re

iRhythm Technologies Announces Chief Financial Officer Transition

Exhibit 99.2 iRhythm Technologies Announces Chief Financial Officer Transition SAN FRANCISCO, August 1, 2024 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He

Amended and Restated Certificate of Incorporation, as amended, of the Registrant.

IRHYTHM TECHNOLOGIES, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION iRhythm Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: A. The name of the Corporation is iRhythm Technologies, Inc., and the original Certificate of Incorporation of this Corporation was filed with the Secretary of State of

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.

exhibit31-chartercertifi CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IRHYTHM TECHNOLOGIES, INC.

iRhythm Technologies, Inc. Conflict Minerals Report for the reporting period January 1, 2023 to December 31, 2023.

Exhibit 1.01 iRhythm Technologies Inc. Conflict Minerals Report For the Reporting Period from January 1, 2023 to December 31, 2023 This Conflict Minerals Report, ("Report"), of iRhythm Technologies Inc., ("the Company", “we” or “our”), for the period January 1, 2023 to December 31, 2023, ("the Reporting Period"), has been prepared pursuant to Rule 13p-1, ("Rule 13p-1" or "the Rule"), under the Sec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 699 8th Street, Suite 600 San Francisco, California 94103 (Address of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of R

iRhythm Technologies Announces First Quarter 2024 Financial Results

Exhibit 99.1 iRhythm Technologies Announces First Quarter 2024 Financial Results SAN FRANCISCO, May 2, 2024 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights •Revenue of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

2023 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ FORM 10-K ____________________________________________

p04413irtcx10kwrapx2024 2023 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

IRHYTHM ANNOUNCES CLOSING OF $661.25 MILLION OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2029, INCLUDING FULL EXERCISE OF INITIAL PURCHASERS’ $86.25 MILLION OPTION TO PURCHASE ADDITIONAL NOTES

Exhibit 99.2 IRHYTHM ANNOUNCES CLOSING OF $661.25 MILLION OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2029, INCLUDING FULL EXERCISE OF INITIAL PURCHASERS’ $86.25 MILLION OPTION TO PURCHASE ADDITIONAL NOTES SAN FRANCISCO, MARCH 8, 2024 (GLOBE NEWSWIRE) – iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict

[Signature Page to [Base][Additional] Capped Call Confirmation]

Exhibit 99.1 [Dealer name and address] [March ], 2024 To: iRhythm Technologies, Inc. 699 8th Street, Suite 600 San Francisco, CA 94103 Attention: Legal Department Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [] (“Dealer”) and iRhythm Technologies,

Indenture dated March 7, 2024 between iRhythm Technologies, Inc. and U.S. Bank Trust Company, National Association, as trustee (including the form of 1.50% Convertible Senior Notes due 2029).

Exhibit 4.1 IRHYTHM TECHNOLOGIES, INC. 1.50% CONVERTIBLE SENIOR NOTES DUE 2029 INDENTURE DATED AS OF MARCH 7, 2024 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 10 Section 1.03. Rules of Construction 11 Section 1.04. References to Additional Interest 1

IRHYTHM PRICES UPSIZED OFFERING OF $575.0 MILLION OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2029

Exhibit 99.1 IRHYTHM PRICES UPSIZED OFFERING OF $575.0 MILLION OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2029 SAN FRANCISCO, MARCH 4, 2024 (GLOBE NEWSWIRE) – iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict and help prevent disease, announced today the pricing of its offering of $575.0 million aggreg

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

IRHYTHM ANNOUNCES PROPOSED OFFERING OF $450.0 MILLION OF CONVERTIBLE SENIOR NOTES

Exhibit 99.1 IRHYTHM ANNOUNCES PROPOSED OFFERING OF $450.0 MILLION OF CONVERTIBLE SENIOR NOTES SAN FRANCISCO, MARCH 4, 2024 (GLOBE NEWSWIRE) – iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and help prevent disease, announced today that it intends to offer, subject to market conditions and othe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 iRhythm Technologie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Technol

List of Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries iRhythm Technologies Limited Company Name Place of Incorporation iRhythm Technologies Limited United Kingdom iRhythm Singapore PTE. Ltd. Singapore iRhythm Japan GK (1) Japan iRhythm Philippines, Inc. (1) Philippines (1) This an indirect subsidiary through iRhythm Singapore PTE. Ltd.

Amended and Restated Certificate of Incorporation of the Registrant, as amended.

Exhibit 3.1 IRHYTHM TECHNOLOGIES, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION iRhythm Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: A. The name of the Corporation is iRhythm Technologies, Inc., and the original Certificate of Incorporation of this Corporation was filed with the Secretary

Compensation Recovery Policy

Exhibit 97.1 iRhythm Technologies, Inc. Compensation Recovery Policy (Adopted August 10, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement resulting from material no

iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results SAN FRANCISCO, February 22, 2024 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 202

Amendment to the Third Amended and Restated Loan and Security Agreement dated

Exhibit 10.8 THIRD AMENDMENT TO THIRD AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This Third Amendment to Third Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into this 17th day of November, 2023, by and between SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY (“Bank”) and IRHYTHM TECHNOLOGIES, INC., a Delaware corporation (“Borrower”), wh

dated May 31, 2019 between the Registrant and Big Dog Holdings LLC.

Exhibit 10.10 First Amendment to Office Lease This First Amendment to Office Lease (this “Amendment”) is being signed on May 31, 2019 (the “Effective Date”), by Big Dog Holdings LLC, a Delaware limited liability company (“Landlord”), and iRhythm Technologies, Inc., a Delaware corporation (“Tenant”). Recitals A.Pursuant to that certain Office Lease dated as of October 4, 2018 (the “Existing Lease”;

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or orga

Executive Change in Control and Severance Policy as Amended.

Exhibit 10.17 IRHYTHM TECHNOLOGIES, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY (Adopted on August 1, 2019; Effective as of September 1, 2019; Amended May 23, 2023) This Executive Change in Control and Severance Policy, as amended (the “Policy”) is designed to provide certain protections to a select group of key employees of iRhythm Technologies, Inc. (“iRhythm” or the “Company”) or any

IRTC / iRhythm Technologies, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01228-irhythmtechnologiesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: iRhythm Technologies Inc Title of Class of Securities: Common Stock CUSIP Number: 450056106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

IRTC / iRhythm Technologies, Inc. / SANDS CAPITAL MANAGEMENT, LLC Passive Investment

SC 13G/A 1 irtc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO Section 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3) * iRhythm Technologies, Inc. (Name of Issuer) Common Stock, par v

JOINT FILING AGREEMENT

EX-99.1 2 d758132dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTIS

IRTC / iRhythm Technologies, Inc. / Artisan Partners Limited Partnership - SC 13G Passive Investment

SC 13G 1 d758132dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No.   )* iRhythm Technologies Inc (Name of Issuer) Common Stock (Title of Class of Secur

IRTC / iRhythm Technologies, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* iRhythm Technologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 450056106 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

IRTC / iRhythm Technologies, Inc. / BlackRock Inc. Passive Investment

us4500561067012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) IRHYTHM TECHNOLOGIES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 450056106 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

Credit, Security and Guaranty Agreement, dated January 3, 2024, by and among the Company, Braidwell Transaction Holdings LLC – Series 5 and Wilmington Trust, National Association.

Exhibit 10.1 Execution Version CREDIT, SECURITY AND GUARANTY AGREEMENT dated as of January 3, 2024 among IRHYTHM TECHNOLOGIES, INC., as the Borrower, any guarantor that hereafter becomes party hereto, each as Guarantor, and collectively as Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO and WILMINGTON TRUST, NATIONAL ASSOCIATION, as the Agent TABLE OF CONTENTS ARTICLE I DEFINITIONS AND ACCO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2024 iRhythm Technolog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2024 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organi

Exhibit 99.1 iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, JANUARY 8, 2024 (GLOBE NEWSWIRE) – iRhythm Technologies, Inc. (NASDAQ:IRTC), a

Exhibit 99.1 iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, JANUARY 8, 2024 (GLOBE NEWSWIRE) – iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary four

Amended and Restated Bylaws of the Registrant (as amended and restated on November 10, 2023).

AMENDED AND RESTATED BYLAWS OF IRHYTHM TECHNOLOGIES, INC. (As Amended and Restated on November 10, 2023) i TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES........................................................................................1 1.1 REGISTERED OFFICE...........................................................................................1 1.2 OTHER OFFICES ...................

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or orga

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

iRhythm Technologies Announces Third Quarter 2023 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Third Quarter 2023 Financial Results SAN FRANCISCO, November 2, 2023 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Financial Highl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of Re

iRhythm Technologies Announces Second Quarter 2023 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Second Quarter 2023 Financial Results SAN FRANCISCO, August 3, 2023 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and six months ended June 30, 2023. Second Quarter 2023 Financial Results •Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 iRhythm Technologi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 iRhythm Technologies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

Exhibit 99.1 iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments SAN FRANCISCO, JUNE 6, 2023 (GLOBE NEWSWIRE) – iRhythm Technologies, Inc.(NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as dire

iRhythm Technologies, Inc. Conflict Minerals Report for the reporting

Exhibit 1.01 iRhythm Technologies Inc. Conflict Minerals Report For the Reporting Period from January 1, 2022 to December 31, 2022 This Conflict Minerals Report, ("Report"), of iRhythm Technologies Inc., (" the Company", “we” or “our”), for the period January 1, 2022 to December 31, 2022, ("the Reporting Period"), has been prepared pursuant to Rule 13p-1, ("Rule 13p-1" or "the Rule"), under the Se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 699 8th Street, Suite 600 San Francisco, California 94103 (Address of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 iRhythm Technologies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2023 iRhythm Technologies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

Resignation, Release and Consulting Agreement, dated March 10, 2023, by and between the Registrant and Douglas Devin

Exhibit 10.1 March 10, 2023 Re: Resignation and Release Agreement Dear Douglas: This letter confirms the agreement (“Agreement”) between you and iRhythm Technologies, Inc., a Delaware corporation (the “Company”) concerning the terms of your resignation and offers you the separation compensation, benefits, and consulting agreement we discussed in exchange for a general release of claims and covenan

iRhythm Technologies Announces First Quarter 2023 Financial Results

Exhibit 99.1 iRhythm Technologies Announces First Quarter 2023 Financial Results SAN FRANCISCO, May 4, 2023 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported financial results for the three months ended March 31, 2023. First Quarter 2023 Financial Results •Revenue of $11

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2023 iRhythm Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 iRhythm Technologi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 iRhythm Technologi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Technol

Offer Letter, dated July 18,2022, by and between the Registrant and Chad Patterson.

Exhibit 10.21 Dear Chad Patterson, We are pleased to offer you the position of Chief Commercial Officer with iRhythm Technologies, Inc. (the “Company”). If you decide to join us, you will receive a salary and certain employee benefits as explained in Exhibit A. You should note that the Company may modify job titles, salaries, and benefits from time to time as it deems necessary. If you decide to j

Offer Letter, dated July 22, 2022, by and between the Registrant and Brice Bobzien.

Exhibit 10.22 Dear Brice Bobzien, We are pleased to offer you the position of Chief Financial Officer with iRhythm Technologies, Inc. (the “Company”). If you decide to join us, you will receive a salary and certain employee benefits as explained in Exhibit A. You should note that the Company may modify job titles, salaries, and benefits from time to time as it deems necessary. If you decide to joi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 iRhythm Technol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or orga

Offer Letter, dated April 24, 2022, by and between the Registrant and Minang Pravin Turakhia, MD.

Exhibit 10.20 April 24, 2022 Minang Pravin Turakhia, MD 1490 Southdown Road Hillsborough, CA 94010 Dear Dr. Turakhia: We are pleased to offer you the position of Chief Scientific Officer and Chief Medical Officer with iRhythm Technologies, Inc. (the “Company”). If you decide to join us, you will receive a salary and certain employee benefits as explained in Exhibit A. You should note that the Comp

List of Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries Company Name Country Date of Incorporation Registration No. iRhythm Technologies Inc. US (Delaware) September 14, 2006 4211384 iRhythm Technologies Limited UK March 10, 2016 10055682 iRhythm Singapore Pte. Ltd. Singapore June 24, 2021 202120787H iRhythm Japan GK (1) Japan June 7, 202 #0110-03-014840 (1) Japan is a subsidiary of Singapore

Offer Letter, dated November 15, 2021, by and between the Registrant and Patrick Murphy.

Exhibit 10.19 November 15, 2021 Patrick Michael Murphy via email: [email protected] Dear Patrick: We are pleased to offer you the position of General Counsel of iRhythm Technologies, Inc. (the “Company”). If you decide to join us, you will receive a salary and certain employee benefits as explained in Exhibit A. You should note that the Company may modify job titles, salaries, and benefit

iRhythm Technologies Announces Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Fourth Quarter and Full Year 2022 Financial Results SAN FRANCISCO, February 23, 2023 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 202

IRTC / Irhythm Technologies Inc / SANDS CAPITAL MANAGEMENT, LLC Passive Investment

SC 13G/A 1 13ga2irhythm.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO Section 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2) iRhythm Technologies, Inc. (Name of Issuer) Common Stock, par

IRTC / Irhythm Technologies Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01187-irhythmtechnologiesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: iRhythm Technologies Inc. Title of Class of Securities: Common Stock CUSIP Number: 450056106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box

IRTC / Irhythm Technologies Inc / BlackRock Inc. Passive Investment

SC 13G/A 1 us4500561067013123.txt us4500561067013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) IRHYTHM TECHNOLOGIES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 450056106 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropria

IRTC / Irhythm Technologies Inc / MACKENZIE FINANCIAL CORP - ANNUAL 13G IRHYTHM TECHNOLOGIES INC. Passive Investment

SC 13G/A 1 irhythm.txt ANNUAL 13G IRHYTHM TECHNOLOGIES INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. Two)* iRhythm Technologies Inc (Name of Issuer) Common Shares (Title of Class of Securities) 450056106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check

IRTC / Irhythm Technologies Inc / JPMORGAN CHASE & CO - FILING IRHYTHM TECHNOLOGIES, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* iRhythm Technologies, Inc. (Name of Issuer) Common Stock, Par Value $.001 Per Share (Title of Class of Securities) 450056106 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name

iRhythm Technologies Announces Third Quarter 2022 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Third Quarter 2022 Financial Results SAN FRANCISCO, November 1, 2022 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported financial results for the three months ended September 30, 2022. Third Quarter 2022 Financial Results ?Reven

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or org

2022 Analyst & Investor Day September 21, 2022 2© 2022 iRhythm Technologies, Inc. Welcome DAN WILSON Executive Vice President, Corporate Strategy 3© 2022 iRhythm Technologies, Inc. Safe Harbor Certain data in this presentation was obtained from vario

2022 Analyst & Investor Day September 21, 2022 2? 2022 iRhythm Technologies, Inc. Welcome DAN WILSON Executive Vice President, Corporate Strategy 3? 2022 iRhythm Technologies, Inc. Safe Harbor Certain data in this presentation was obtained from various external sources, and neither iRhythm Technologies, Inc. (?iRhythm? or the ?Company?) nor its affiliates or representatives has verified such data

iRhythm Technologies Details Growth Strategies at 2022 Analyst & Investor Day

Exhibit 99.1 iRhythm Technologies Details Growth Strategies at 2022 Analyst & Investor Day SAN FRANCISCO, September 21, 2022 ? iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent and predict disease, will discuss the Company?s strategies for long-term growth, provide an update on its innovation pipeline and sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of Re

iRhythm Technologies Announces Second Quarter 2022 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Second Quarter 2022 Financial Results SAN FRANCISCO, August 4, 2022 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2022. Second Quarter 2022 Financial Highlights ?Revenue of $102.1 million, a 25.6%

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

Offer Letter between the Company and Brice Bobzien dated July 25, 2022

Exhibit 10.1 Dear Brice Bobzien, We are pleased to offer you the position of Chief Financial Officer with iRhythm Technologies, Inc. (the ?Company?). If you decide to join us, you will receive a salary and certain employee benefits as explained in Exhibit A. You should note that the Company may modify job titles, salaries, and benefits from time to time as it deems necessary. If you decide to join

iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence

iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) ? iRhythm Technologies, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

Resignation and Release of Claims by and between iRhythm Technologies, Inc. and David A. Vort, dated July 18, 2022

Exhibit 10.1 RESIGNATION AND RELEASE OF CLAIMS This Resignation and Release of Claims (?Agreement?) is made by and between David Vort (?Employee?) and iRhythm Technologies, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an invention assignment and confidentia

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

iRhythm Technologies Announces Chief Commercial Officer Transition and Schedules Second Quarter Earnings Release and Conference Call for August 4, 2022

iRhythm Technologies Announces Chief Commercial Officer Transition and Schedules Second Quarter Earnings Release and Conference Call for August 4, 2022 SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) ? iRhythm Technologies, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction

SD 1 d330080dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 699 8th Street, Suite 600 San Francisco, Calif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of R

iRhythm Technologies Announces First Quarter 2022 Financial Results

Exhibit 99.1 iRhythm Technologies Announces First Quarter 2022 Financial Results SAN FRANCISCO, May 5, 2022 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended March 31, 2022. First Quarter 2022 Financial Highlights ?Revenue of $92.4 million, a 24.3% incre

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 IRHYTHM TECHNOLOGIES, INC. 699 8th Street, Suite 600 San Francisco, California 94103

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Stateme

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

iRhythm Technologies Announces Amendment to Term Loan Agreement Provides enhanced credit facility up to $100 million with favorable terms and facility maturity extended to March 2027

Exhibit 99.1 iRhythm Technologies Announces Amendment to Term Loan Agreement Provides enhanced credit facility up to $100 million with favorable terms and facility maturity extended to March 2027 SAN FRANCISCO, March 29, 2022 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, announced it has amended its existing

Second Amendment to the Third Amended and Restated Loan and Security Agreement dated March 28, 2022, by and between the Company and Silicon Valley Bank.

SECOND AMENDMENT TO THIRD AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This Second Amendment to Third Amended and Restated Loan and Security Agreement (this ?Amendment?) is entered into this 28th day of March, 2022, by and between SILICON VALLEY BANK (?Bank?) and IRHYTHM TECHNOLOGIES, INC.

Resignation and Release Agreement, dated March 13, 2022, between iRhythm Technologies, Inc. and Kevin M. King.

Exhibit 10.1 RESIGNATION AND RELEASE AGREEMENT This Resignation and Release Agreement (?Agreement?) is made by and between Kevin King (?Mr. King?) and iRhythm Technologies, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). 1.Resignation. Effective as of April 1, 2022 (the ?Effective Date?), Mr. King will resign from the Company?s Board of Di

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

iRhythm® Technologies Announces Kevin King to Retire from Board of Directors

iRhythm? Technologies Announces Kevin King to Retire from Board of Directors SAN FRANCISCO, March 14, 2022 - iRhythm Technologies, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Techn

Second Amendment to Development Collaboration Agreement by and among the Registrant, Verily Life Sciences LLC and Verily Ireland Limited.

***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed*** AMENDMENT NO.

Calculation of Filing Fee Tables

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) iRhythm Technologies, Inc (Exact name of registrant as specified in its charter) Table 1 ? Newly Registered Securities Security Type Securities Class Type Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Technol

As filed with the Securities and Exchange Commission on February 28, 2022

As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.

First Amendment to Development Collaboration Agreement by and among the Registrant, Verily Life Sciences LLC and Verily Ireland Limited.

***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed*** AMENDMENT NO.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2022 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or orga

iRhythm Technologies Announces Fourth Quarter and Full Year 2021 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Fourth Quarter and Full Year 2021 Financial Results SAN FRANCISCO, February 23, 2022 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months and full year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights ?

IRTC / Irhythm Technologies Inc / SANDS CAPITAL MANAGEMENT, LLC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO Section 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No.1) iRhythm Technologies, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 450056106 (CUS

IRTC / Irhythm Technologies Inc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) iRhythm Technologies, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 450056106 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc

IRTC / Irhythm Technologies Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: iRhythm Technologies Inc. Title of Class of Securities: Common Stock CUSIP Number: 450056106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

IRTC / Irhythm Technologies Inc / MACKENZIE FINANCIAL CORP - 13G ANNUAL - IRHYTHM TECHNOLOGIES Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. One)* iRhythm Technologies Inc (Name of Issuer) Common Shares (Title of Class of Securities) 450056106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

IRTC / Irhythm Technologies Inc / BlackRock Inc. Passive Investment

us4500561067020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) IRHYTHM TECHNOLOGIES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 450056106 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

IRTC / Irhythm Technologies Inc / JPMORGAN CHASE & CO - FILING IRHYTHM TECHNOLOGIES, INC. Passive Investment

SC 13G 1 iRhythmTechnologiesInc.h.htm FILING IRHYTHM TECHNOLOGIES, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* iRhythm Technologies, Inc. (Name of Issuer) Common Stock, Par Value $.001 Per Share (Title of Class of Securities) 450056106 (CUSIP Number) December 31, 2021 (Date of Event Which Requ

Promotion Letter, executed December 9, 2021, between iRhythm Technologies, Inc. and Douglas J. Devine.

December 8, 2021 VIA EMAIL Dear Doug: You are being offered the position of Chief Operating Officer (?COO?) of iRhythm Technologies, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

Promotion Letter, executed December 10, 2021, between iRhythm Technologies, Inc. and David A. Vort.

December 8, 2021 VIA EMAIL Dear Dave: You are being offered the position of Chief Commercial Officer (?CCO?) of iRhythm Technologies, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name

Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organ

iRhythm Technologies Announces Third Quarter 2021 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Third Quarter 2021 Financial Results SAN FRANCISCO, November 4, 2021 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended September 30, 2021. Third Quarter 2021 Financial Highlights ?Revenue was $85.4 million, a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organi

iRhythm® Technologies Announces Changes to Its Board of Directors Karen Ling Appointed to the Board; Raymond Scott to Retire

iRhythm? Technologies Announces Changes to Its Board of Directors Karen Ling Appointed to the Board; Raymond Scott to Retire SAN FRANCISCO, October 12, 2021 - iRhythm Technologies, Inc.

iRhythm® Technologies Names Quentin Blackford President and Chief Executive Officer Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Financial Execution with High Growth Companies

iRhythm? Technologies Names Quentin Blackford President and Chief Executive Officer Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Financial Execution with High Growth Companies SAN FRANCISCO, September 13, 2021 - iRhythm Technologies, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2021 iRhythm Techno

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or org

Offer Letter, dated September 8, 2021, by and between the Registrant and Quentin S. Blackford.

September 8, 2021 Dear Quentin: We are pleased to offer you the position of President and Chief Executive Officer of iRhythm Technologies, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT iRhythm Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 699 8th Street, Suite 600 San Francisco, California 94103 (Address of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of Re

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

iRhythm Technologies Announces Second Quarter 2021 Financial Results

Exhibit 99.1 iRhythm Technologies Announces Second Quarter 2021 Financial Results SAN FRANCISCO, August 5, 2021 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2021. Second Quarter 2021 Financial Highlights ?Revenue was $81.3 million, a 59.8%

IRTC / Irhythm Technologies Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* iRhythm Technologies, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 450056106 (CUSIP Number) Eddie C. Brow

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

Consulting Agreement by and between the Company and Michael Coyle dated June 29, 2021

IRHYTHM TECHNOLOGIES, INC. CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is made and entered into as of June 7, 2021 (the ?Effective Date?) by and between iRhythm Technologies, Inc., a Delaware corporation with its principal place of business at 699 8th Street, Suite 600, San Francisco California (the ?Company?), and Michael Coyle, an individual (?Consultant?) (each herein refe

Separation Agreement and Release by and between the Company and Michael Coyle dated June 29, 2021

SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Michael J.

Offer Letter dated July 2, 2021 by and between the Company and Douglas Devine

July 2, 2021 VIA EMAIL Douglas J. Devine, CPA 12 Keefer Court Piedmont, CA 94610 Dear Doug: You have agreed to serve as Interim Chief Executive Officer (?Interim CEO?) of iRhythm Technologies, Inc. (the ?Company?) during the Company?s search for a Chief Executive Officer. This letter sets forth the terms and conditions of the Interim CEO role, which is in addition to your role as Chief Financial O

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiza

As filed with the Securities and Exchange Commission on June 3, 2021

As filed with the Securities and Exchange Commission on June 3, 2021 Registration No.

iRhythm® Technologies Announces Leadership Transition President and CEO Michael Coyle Steps Down Due to Personal Matters Douglas Devine to Serve as Interim CEO While Search for Permanent CEO is Conducted

Exhibit 99.1 iRhythm? Technologies Announces Leadership Transition President and CEO Michael Coyle Steps Down Due to Personal Matters Douglas Devine to Serve as Interim CEO While Search for Permanent CEO is Conducted SAN FRANCISCO, June 1, 2021 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced tha

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizat

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of R

Multi-Tenant Office/Industrial Lease by and between iRhythm Technologies, Inc. and Katella/Holder Street LLC dated March 18, 2021.

MULTI-TENANT OFFICE/INDUSTRIAL LEASE (NNN) CYPRESS DISTRIBUTION CENTER Cypress, California LANDLORD: KATELLA/HOLDER STREET, LLC, a Delaware limited liability company TENANT: IRHYTHM TECHNOLOGIES, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organizati

IRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) March 31, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 137,375 $ 88,628 Short-term investments 124,911 246,5

Exhibit 99.1 iRhythm Technologies Announces First Quarter 2021 Financial Results SAN FRANCISCO, May 6, 2021 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended March 31, 2021. First Quarter 2021 Financial Highlights ?Revenue was $74.3 million, a 17% incre

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or organiz

iRhythm® Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas’s Updated Rate Publication and Provides Commentary on Results for the First Quarter 2021

Exhibit 99.1 iRhythm? Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas?s Updated Rate Publication and Provides Commentary on Results for the First Quarter 2021 SAN FRANCISCO, April 12, 2021 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, commented on the recent publication by

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Technol

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2021 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37918 20-8149544 (State or other jurisdiction of incorporation or orga